New model may better predict outcomes for children with autism and autistic spectrum disorders

A new classification tool may allow healthcare professionals treating children with autism and autism-related disorders to more systematically sort out the combination of traits in the condition, and to better predict how children may improve over time. If the model holds up to further study, it may also allow researchers to gauge the effectiveness of different autism treatments.

Developmental pediatrician James Coplan, M.D., reports on a study of 91 children he saw between 1997 and 2002 at the Regional Autism Center of The Children's Hospital of Philadelphia. Most patients were pre-schoolers or of elementary school age, and predominantly boys. The study appears in the July 2005 issue of Pediatrics.

The children in the study had autistic spectrum disorders (ASD), a group of neurodevelopmental disorders of impaired social communication. Those disorders include classic autism, pervasive developmental disorder and Asperger's syndrome. Dr. Coplan studied the relationship among three variables: the severity of the disorder (called atypicality), general intelligence (measured as IQ or developmental quotient) and time.

"These disorders are dynamic and change over time," says Dr. Coplan. "Although they are traditionally classified into mutually exclusive diagnostic boxes, they tend to blend into each other, and this model provides a way to look continuously at ASD, as the symptoms occur and develop along the autistic spectrum, and as the symptoms change over time."

Some children have severe autistic symptoms but high intelligence; others have mild symptoms and mental retardation, or combinations in between, he added. In explaining the model to parents, he sometimes draws an analogy to weight and height. Just as each individual can have a different combination of weight and stature, someone can have an individual combination of intelligence and degree of autism.

One central finding of the study, said Dr. Coplan, is that children in the'"/>

(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...

(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...

(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick Taché ... Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is a ... & Medical Technology Group have been featured speakers at every DeviceTalks conference since 2011. ...

(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...

(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...

(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...

(Date:12/8/2016)... -- Global Interventional Radiology Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...

(Date:12/8/2016)... Dec. 8, 2016 Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...